We'll see how this plays out given the Admin's new freeze on visas from 75 countries. While they say this new freeze won't impact tourist visas, we all know that policy changes often occur with little or no notice. If I were ex-US, I'd sadly think twice before making plans to attend the World Cup.

This misleading narrative ignores expected biosimilar launches, ignores the unprecedented medical innovations resulting from significant additional R&D investments, & ignores the value to patients of improved drug delivery. This narrative also fails to talk about PBM abuses--the real cost driver.

I-MAK ignores the significant competition in this space and biosimilars in development. More importantly, I-MAK fails to raise concerns about PBM abuses which are the real drivers of patient OOP costs. As usual, I-MAK ignores the fact that the # of patents didn't impede competitors' market entry.

US leads the world in innovation because of complementary roles of public and private sector. When private sector being hit with tariffs and other policies like price controls increasing uncertainty and costs of doing business we are already seeing impacts on VC deals and on small firms.

....and if the President's budget request is approved we'll see NIH cut by 40 percent--we'll lose vital infrastructure and impede the pace of medical innovation & be handing over a competitive advantage to China at the expense of US patients and the US economy. We need more people speaking out.